Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
GC Biopharma Enters Phase 2 for Homegrown mRNA Vaccine, Targets 2028 Rollout
3+ day, 3+ hour ago (213+ words) First Patient Dosing to Begin This Year, Phase 3 IND Filing Planned for Next Year Domestic Vaccine Self-Sufficiency and Proprietary mRNA-LNP Platform Sovereignty GC Biopharma said on the 11th that the Ministry of Food and Drug Safety had approved the investigational new…...
How past Endpoints 11 winners fared as the biotech industry rebounded
3+ day, 17+ hour ago (64+ words) Endpoints News How past Endpoints 11 winners fared as the biotech industry rebounded We’ll be unveiling this year’s Endpoints 11 in Boston on the night of Sept. 24. Join us. Think we're worth reading…...
Life Sciences M&A Hits Record High in 2026
3+ day, 22+ hour ago (568+ words) Life sciences dealmaking hits record highs as biopharma bets big on early-stage assets amid geopolitical uncertainty. The first half of 2026 has delivered the strongest run of life sciences dealmaking on record, according to a report published by EY - a long-term…...
Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
4+ day, 15+ hour ago (47+ words) Published on 09/09/2026 at 11:59 am EDT Moderna Soars 129% for the Week | Closing Bell August 21, 2026 at 05:02 pm EDT Will Moderna Wake Up the Health Care Sector? Moderna and Merck & Co are the stocks of the day on Wall Street...
Three’s a party! Medtech BCal woos Genetic Signatures, Sonic’s Microba
4+ day, 19+ hour ago (110+ words) AFR If you can’t beat ’em, join ’em. BCAL Diagnostics’ plans to nab fellow ASX-listed biotech Genetic Signatures hit the skids after revelations the target was already flirting with Sonic Healthcare-backed Microba Life Sciences. There’s an FDA approval in the…...
Oxford University cancer vaccine firm celebrates $500K USD investment
6+ day, 12+ hour ago (442+ words) An Oxford University cancer firm is celebrating a $500K investment from one of its shareholders, which will allow it to continue its research. Dr Tony Coombs, chair of Oxford Vacmedix UK Limited, a company based at Oxford Science Park, said he…...
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
1+ week, 1+ day ago (433+ words) The FDA approved a therapy from Revolution Medicines that slows a cancer that kills seven of out eight patients within five years The excitement surrounding Moderna and Merck ’s personalized mRNA cancer vaccine added more than $50 billion in combined market…...
MRNA Looks 503.4% Overvalued on GF Value™
1+ week, 1+ day ago (304+ words) On September 05, 2026, the healthcare sector surged 4.91% in August, outpacing the S&P 500’s 2.68% gain, driven largely by biotechnology breakthroughs. Moderna Inc (NASDAQ: MRNA) led the charge with a remarkable 156.0% rally following promising interim results from its mRNA cancer vaccine trial. The…...
Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance
1+ week, 1+ day ago (913+ words) Moderna and Merck's personalized mRNA cancer vaccine mRNA-4157 achieved a breakthrough in Phase 3 trials, triggering a sharp rally in oncology sequencing and diagnostics stocks. Tempus AI, positioned as a potential sequencing partner, surged 24%, while its acquisition of Personalis has come…...
Transgene jumps 20% on positive cancer vaccine data in early trial
1+ week, 3+ day ago (191+ words) Sept 3 (Reuters) – Transgene shares surged 20% in early Paris trading on Thursday, after the French biotechnology company reported positive Phase 1 trial data on its vaccine candidate for head and neck cancer. Investors have rewarded encouraging data from other personalised cancer-vaccine programmes…...